Skip to main content
. 2015 Sep 19;60(11):3408–3417. doi: 10.1007/s10620-015-3868-5

Fig. 1.

Fig. 1

Patient disposition. The safety population for the budesonide foam group (n = 719) included the budesonide foam groups in the two placebo-controlled trials (n = 268) and two active-controlled trials (n = 387), and the placebo-crossover group (n = 64) in the open-label extension study. The safety population for the placebo group (n = 278) included patients from two placebo-controlled trials